Grifols (GRFS) Competitors

Grifols (NASDAQ:GRFS) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Which has more volatility and risk, GRFS or BNTX?

Grifols has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Which has better valuation & earnings, GRFS or BNTX?

Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$7.81B	0.95	$169.80M	$1.17	9.18
BioNTech	$2.98B	9.10	-$719.92M	-$1.60	-70.44

Does the media favor GRFS or BNTX?

In the previous week, BioNTech had 8 more articles in the media than Grifols. MarketBeat recorded 14 mentions for BioNTech and 6 mentions for Grifols. Grifols' average media sentiment score of 0.94 beat BioNTech's score of 0.40 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals hold more shares of GRFS or BNTX?

15.5% of BioNTech shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is GRFS or BNTX more profitable?

Grifols has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	N/A	N/A	N/A
BioNTech	-12.20%	-1.84%	-1.59%

Do analysts recommend GRFS or BNTX?

Grifols presently has a consensus price target of $10.30, suggesting a potential downside of 4.10%. BioNTech has a consensus price target of $135.80, suggesting a potential upside of 20.50%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

Grifols beats BioNTech on 9 of the 17 factors compared between the two stocks.